BCL2 and B-cell non-Hodgkin lymphoma: Alternative strategies to inhibit HKII such as: 1) down-regulation of HKII using novel and more potent mTOR inhibitors, or 2) selective inhibition of the HKII binding domain or disrupting its interaction with Bcl-2 family members or VDAC may result in significant anti-tumor activity in B-cell lymphoma.